Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Sabirnetug
Therapeutic Area : Neurology
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Acumen Completes ALTITUDE-AD Phase 2 Enrollment for Sabirnetug in Alzheimer’s
Details : ACU193 (sabirnetug) is a humanized monoclonal antibody (mAb), it selectively targets toxic soluble AβOs which is the primary underlying cause of the neurodegenerative process in alzheimer’s disease.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
March 26, 2025
Lead Product(s) : Sabirnetug
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sabirnetug,Hyaluronidase Enzyme
Therapeutic Area : Neurology
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Acumen Reports Phase 1 Data for Subcutaneous Sabirnetug in Healthy Volunteers
Details : ACU193 (sabirnetug) is a humanized monoclonal antibody (mAb), it selectively targets toxic soluble AβOs which is the primary underlying cause of the neurodegenerative process in alzheimer’s disease.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
March 19, 2025
Lead Product(s) : Sabirnetug,Hyaluronidase Enzyme
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sabirnetug
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Lonza Group
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
Acumen Pharmaceuticals Extends Alzheimer’s Collaboration with Lonza
Details : The collaboration aims to enable the potential future commercial launch of ACU193 (sabirnetug), the first humanized mAb to clinically demonstrate selective target engagement of amyloid beta oligomers.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
September 27, 2024
Lead Product(s) : Sabirnetug
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Lonza Group
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
Lead Product(s) : Sabirnetug
Therapeutic Area : Neurology
Study Phase : Phase II
Recipient : Lonza Biologics Inc
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
Acumen Pharma Extends Lonza Collaboration for Drug Manufacturing of Sabirnetug
Details : Acumen collaborates with Lonza to advance the clinical development and potential future commercial launch of ACU193 (sabirnetug), which is being evaluated for Alzheimer’s disease.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
September 26, 2024
Lead Product(s) : Sabirnetug
Therapeutic Area : Neurology
Highest Development Status : Phase II
Recipient : Lonza Biologics Inc
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
Acumen Pharmaceuticals Doses First Subject in Phase 1 Study of Sabirnetug for Alzheimer’s
Details : ACU193 (sabirnetug) is a humanized monoclonal antibody (mAb), it selectively targets toxic soluble AβOs which is the primary underlying cause of the neurodegenerative process in alzheimer’s disease.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
July 29, 2024
Details : Sabirnetug is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Alzheimer Disease.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
July 22, 2024
Lead Product(s) : Sabirnetug
Therapeutic Area : Neurology
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Acumen Doses First Patient In Phase 2 Of Sabirnetug In Early Alzheimer's Disease
Details : ACU193 (sabirnetug) is a humanized monoclonal antibody (mAb), it selectively targets toxic soluble AβOs which is the primary underlying cause of the neurodegenerative process in alzheimer’s disease.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
May 08, 2024
Lead Product(s) : Sabirnetug
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sabirnetug
Therapeutic Area : Neurology
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Acumen Doses First Patient in ALTITUDE-AD Phase 2 Trial for Early Alzheimer’s
Details : ACU193 (sabirnetug) is a humanized monoclonal antibody that targets toxic soluble amyloid beta oligomers. It is being evaluated for the treatment of early alzheimer’s disease.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
May 08, 2024
Lead Product(s) : Sabirnetug
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sabirnetug
Therapeutic Area : Neurology
Study Phase : Phase II
Recipient : Lonza Biologics Inc
Deal Size : Undisclosed
Deal Type : Collaboration
Acumen Pharmaceuticals Collaborates with Lonza for Sabirnetug in Alzheimer's Disease
Details : Lonza will manufacture ACU193, a monoclonal antibody targeting toxic amyloid beta oligomers, for Alzheimer’s disease treatment.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
April 04, 2024
Lead Product(s) : Sabirnetug
Therapeutic Area : Neurology
Highest Development Status : Phase II
Recipient : Lonza Biologics Inc
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Sabirnetug is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Alzheimer Disease.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
March 28, 2024